Registration approvals of Simvastatin & Betahistine in the cholesterol lowering agents and the anti-vertigo categories, respectively were gained in June 2008.
Tabuk is preparing now for the launch of the first wave of products in the private sector in QAT 4/ 2008. By mid 2009, there will be a total of five physically active products in the market.